digestVidSign in
summary

UCLA Health - Acute Severe Ulcerative Colitis Novel Approaches | UCLA Digestive Diseases

Thumbnail of the video “UCLA Health - Acute Severe Ulcerative Colitis Novel Approaches | UCLA Digestive Diseases”
Community upload. AI output has not been independently verified.
Author: UCLA Health
Categories: Health
Tags: health
Views: 2 · Last viewed: 2026-10-16 15:00 UTC

Short Summary

Main recommendation: For acute severe ulcerative colitis that does not respond to IV corticosteroids (60 mg total dose), the speaker presents newer rescue options, centering on JAK inhibitors (tofacitinib and upadacitinib) as a day-three rescue therapy, alongside higher-dose infliximab (10 mg/kg) and cheaper older drugs (cyclosporine, tacrolimus) as bridge options. The talk frames these as emerging approaches from University of Michigan guidelines, with limited robust evidence and no FDA approval for the inpatient JAK use described.

Key Points

  • Diagnosis uses the Travis criteria; bloody stools clearly met them in the presented case, with fever, tachycardia, anemia, or elevated inflammatory markers as further considerations (markers can be normal in up to 20% of patients).
  • Standard care is IV corticosteroids, with infliximab usually introduced on day three as primary rescue; surgical consultation is typically recommended around day three.
  • Cyclosporine and tacrolimus are cheaper older drugs with similar colectomy-avoidance rates to infliximab in one comparative study, but they are usually used as bridges rather than maintenance, and cause more side effects.
  • Antibiotics are not recommended in adult acute severe UC by ACG guidelines, though they have some pediatric role; C. diff and CMV should always be ruled out, and thromboprophylaxis is important given colitis-related thrombotic risk.
  • JAK inhibitors are presented as a newer option: upadacitinib (selective JAK1) is FDA-approved for Crohn's and has second-line approval for acute severe colitis; the speaker says it showed about 2.5 times the clinical remission induction of tofacitinib.

Details Worth Noting

  • Concrete instructions:
    • Rule out C. diff and CMV before escalating therapy.
    • Start IV corticosteroids at 60 mg total dose (pediatric practice also starts corticosteroids at 60 mg IV for most adults).
    • Give thromboprophylaxis; involve surgeons early, with consultation usually around day three.
    • Rescue therapy on day three: infliximab at 10 mg/kg (the speaker's preferred dose for acute severe UC, citing better outcomes at 10 mg/kg than the traditional 5 mg/kg, including significantly better one-year colectomy rates).
    • If using tofacitinib as the JAK option: 10 mg three times daily inpatient; then 10 mg twice daily outpatient for about 12 weeks, then taper or transition. Stop concurrent immunomodulators, hydrate vigorously, give thromboprophylaxis, and monitor CRP (most effect seen within 72 hours; a rising CRP is a poor prognostic sign for colectomy).
    • If using upadacitinib (the speaker's preferred JAK option): 30 mg twice daily; outpatient induction at 45 mg; same monitoring, hydration, and anticoagulation.
    • Do not give tofacitinib to a patient who has been given infliximab; the guidelines recommend holding it, though the speaker notes limited washout overlap may be acceptable in practice.
    • Infliximab follow-up protocol: after the initial 10 mg/kg dose, check CRP and infliximab antibodies at 60–66 hours. If CRP is above 80% of the previous level, proceed to colectomy; if CRP falls, give a second dose at 72 hours; if CRP is below 7, the next dose follows the standard two-week interval.
  • Relative contraindications for JAK inhibitors: history of thrombotic events, pregnancy, toxic megacolon, strong CYP3A4-inducing medications, malignancy, low absolute lymphocyte count (less severe with tofacitinib than some S1P drugs), and severe hepatic or renal impairment.
  • Ideal JAK candidates: patients who failed prior biologics or corticosteroids, have a high CRP-to-albumin ratio, or have immune dysregulation (e.g., trisomy 21, where IBD is described as more interferon-gamma mediated).
  • The JAK inhibitor 85% reduction in 90-day colectomy rates came from tofacitinib at 10 mg three times daily; 10 mg twice daily showed no benefit in that data. The speaker notes the data is not highly robust and there are no RCTs for this inpatient use.
  • Sequential rescue therapy (e.g., cyclosporine then infliximab) in a systematic review of 10 studies (300+ patients) showed a 23% adverse event rate, including serious infections, lower than previously thought.
  • Adalimumab: now has pediatric dosing of 80 mg every two weeks for severe colitis following the VARSITY trial, but the speaker states it has no role in acute severe ulcerative colitis and is still not their go-to for UC generally.
  • Pediatric activity index (PUCAI) assesses abdominal pain, stools per day, nocturnal stooling, and blood in stool.

Bottom Line

Newer JAK-based rescue options and higher-dose infliximab are reshaping day-three management of refractory acute severe ulcerative colitis, but the evidence for inpatient JAK use is limited and should be weighed with surgical input and careful monitoring.